CytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
20 Diciembre 2022 - 4:00PM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of
conditionally activated oncology therapeutics, today announced that
Sean McCarthy, D.Phil., president, chief executive officer, and
chairman, will present at the 41st Annual J.P. Morgan Healthcare
Conference on Wednesday, January 11, 2023 at 3:00 p.m. ET.
A live webcast of the presentation will be available on the
Events and Presentations page of CytomX’s website at
www.cytomx.com. An archived replay will be available for 30 days
following the event. In addition, management will be available for
one-on-one meetings with investors who are registered to attend the
conference.
About CytomX TherapeuticsCytomX is a
clinical-stage, oncology-focused biopharmaceutical company
dedicated to destroying cancer differently. By pioneering a novel
class of conditionally activated biologics, powered by its Probody®
technology platform, CytomX’s goal is to transcend the limits of
current cancer treatments. CytomX’s robust and differentiated
pipeline comprises seven therapeutic candidates across multiple
treatment modalities including antibody-drug conjugates (“ADCs”),
T-cell engaging bispecific antibodies (“TCBs”), and immune
modulators such as cytokines and checkpoint inhibitors (“CPIs”).
CX-2029 is an investigational conditionally activated antibody-drug
conjugate (ADC) directed toward CD71, which has demonstrated
encouraging antitumor activity in patients with squamous non-small
cell lung cancer and is being developed in collaboration with
AbbVie. CytomX’s clinical pipeline also includes cancer
immunotherapeutic candidates against validated targets such as the
CTLA-4-targeting Probody therapeutics, BMS-986249 and BMS-986288,
partnered with Bristol Myers Squibb, as well as CX-904, a
conditionally activated T-cell-engaging bispecific antibody
targeting the epidermal growth factor receptor (EGFR) on tumor
cells and the CD3 receptor on T cells, which is partnered with
Amgen. In addition, CytomX has a diverse preclinical portfolio of
wholly-owned assets including CX-801, an interferon alpha-2b
Probody cytokine that has broad potential applicability in
traditionally immuno-oncology sensitive as well as insensitive
(cold) tumors and CX-2051, a conditionally activated ADC directed
toward EpCAM, with potential applicability across multiple
EpCAM-expressing epithelial cancers. Praluzatamab ravtansine
(CX-2009) is an investigational conditionally activated ADC
directed toward CD166 that demonstrated single agent clinical
activity in a Phase 2 study for patients with advanced
HR+/HER2-non-amplified breast cancer. Following the Phase 2
results, CytomX decided not to further progress praluzatamab
ravtansine alone and is seeking a partner to further develop the
molecule. CytomX has also established strategic collaborations with
multiple leaders in oncology, including AbbVie, Amgen, Astellas,
and Bristol Myers Squibb and Regeneron. For more information about
CytomX and how it is working to make conditionally activated
treatments the new standard-of-care in the fight against cancer,
visit www.cytomx.com and follow us on LinkedIn and Twitter.
CytomX Contact:Chris OgdenSVP,
Finance and Accounting cogden@cytomx.com(317) 767-4764
Investor and Media
Contact:Stern Investor RelationsStephanie
Ascherstephanie.ascher@sternir.com212-362-1200
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024